0.4406
price down icon3.44%   -0.0157
after-market After Hours: .44 -0.0006 -0.14%
loading
Bioatla Inc stock is traded at $0.4406, with a volume of 810.59K. It is down -3.44% in the last 24 hours and up +20.05% over the past month. BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
See More
Previous Close:
$0.4563
Open:
$0.479
24h Volume:
810.59K
Relative Volume:
1.20
Market Cap:
$19.79M
Revenue:
-
Net Income/Loss:
$-123.46M
P/E Ratio:
-0.1701
EPS:
-2.59
Net Cash Flow:
$-104.11M
1W Performance:
+36.07%
1M Performance:
+20.05%
6M Performance:
-77.86%
1Y Performance:
-80.42%
1-Day Range:
Value
$0.422
$0.4799
1-Week Range:
Value
$0.30
$0.4799
52-Week Range:
Value
$0.2601
$3.5299

Bioatla Inc Stock (BCAB) Company Profile

Name
Name
Bioatla Inc
Name
Phone
858-558-0708
Name
Address
11085 TORREYANA ROAD, SAN DIEGO
Name
Employee
61
Name
Twitter
Name
Next Earnings Date
2025-03-21
Name
Latest SEC Filings
Name
BCAB's Discussions on Twitter

Compare BCAB with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
BCAB
Bioatla Inc
0.4406 19.79M 0 -123.46M -104.11M -2.59
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Bioatla Inc Stock (BCAB) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-13-24 Downgrade H.C. Wainwright Buy → Neutral
Sep-15-22 Initiated JMP Securities Mkt Outperform
May-05-22 Downgrade Credit Suisse Outperform → Neutral
Mar-21-22 Initiated H.C. Wainwright Buy
Oct-15-21 Resumed BTIG Research Buy
Jun-28-21 Initiated ROTH Capital Buy
May-05-21 Resumed Credit Suisse Outperform
Apr-26-21 Resumed Credit Suisse Outperform
Jan-11-21 Initiated BTIG Research Buy
Jan-11-21 Initiated Credit Suisse Outperform
Jan-11-21 Initiated JP Morgan Overweight
Jan-11-21 Initiated Jefferies Buy
View All

Bioatla Inc Stock (BCAB) Latest News

pulisher
Apr 25, 2025

BioAtla Inc (BCAB) Could Be Worth Considering For The Next Few Weeks - Stocksregister

Apr 25, 2025
pulisher
Apr 24, 2025

BioAtla announces poster presentations at 2025 AACR meeting - TipRanks

Apr 24, 2025
pulisher
Apr 24, 2025

How did BioAtla Inc (BCAB) fare last session? - uspostnews.com

Apr 24, 2025
pulisher
Apr 24, 2025

BCAB’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com

Apr 24, 2025
pulisher
Apr 24, 2025

BioAtla (BCAB) to Showcase Innovative Cancer Research at 2025 Co - GuruFocus

Apr 24, 2025
pulisher
Apr 24, 2025

BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting - The Manila Times

Apr 24, 2025
pulisher
Apr 24, 2025

Cancer Treatment Breakthrough: BioAtla's Novel Drug Outperforms Standard Therapy in Multiple Cancers - Stock Titan

Apr 24, 2025
pulisher
Apr 23, 2025

BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - The Manila Times

Apr 23, 2025
pulisher
Apr 23, 2025

BioAtla, Inc. to Present Phase 2 Trial Results of Ozuriftamab Vedotin at ASCO 2025 Annual Meeting - Nasdaq

Apr 23, 2025
pulisher
Apr 23, 2025

New Phase 2 Cancer Drug Data: BioAtla's Head and Neck Cancer Treatment Results at ASCO 2025 - Stock Titan

Apr 23, 2025
pulisher
Apr 21, 2025

BioAtla stock holds $1 target, Market Outperform rating By Investing.com - Investing.com Nigeria

Apr 21, 2025
pulisher
Apr 21, 2025

BioAtla stock holds $1 target, Market Outperform rating - Investing.com Australia

Apr 21, 2025
pulisher
Apr 14, 2025

12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga

Apr 14, 2025
pulisher
Apr 13, 2025

Norges Bank Makes New Investment in BioAtla, Inc. (NASDAQ:BCAB) - Defense World

Apr 13, 2025
pulisher
Apr 08, 2025

BioAtla's SWOT analysis: oncology biotech's stock faces pivotal year - Investing.com

Apr 08, 2025
pulisher
Apr 08, 2025

BioAtla’s SWOT analysis: oncology biotech’s stock faces pivotal year By Investing.com - Investing.com South Africa

Apr 08, 2025
pulisher
Apr 08, 2025

BioAtla’s SWOT analysis: oncology biotech’s stock faces pivotal year - Investing.com India

Apr 08, 2025
pulisher
Apr 04, 2025

HC Wainwright Has Optimistic Outlook of BioAtla Q1 Earnings - Defense World

Apr 04, 2025
pulisher
Apr 03, 2025

FY2029 Earnings Estimate for BioAtla Issued By HC Wainwright - Defense World

Apr 03, 2025
pulisher
Apr 01, 2025

BioAtla (NASDAQ:BCAB) Given “Neutral” Rating at HC Wainwright - Defense World

Apr 01, 2025
pulisher
Mar 31, 2025

BioAtla stock price target cut to $1 by Citizens JMP - Investing.com Australia

Mar 31, 2025
pulisher
Mar 31, 2025

Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace

Mar 31, 2025
pulisher
Mar 31, 2025

BioAtla price target lowered to $1 from $5 at Citizens JMP - TipRanks

Mar 31, 2025
pulisher
Mar 29, 2025

BioAtla, Inc. (NASDAQ:BCAB) Q4 2024 Earnings Call Transcript - MSN

Mar 29, 2025
pulisher
Mar 29, 2025

Companies Like BioAtla (NASDAQ:BCAB) Could Be Quite Risky - Yahoo Finance

Mar 29, 2025
pulisher
Mar 28, 2025

BioAtla’s Earnings Call: Clinical Progress and Strategic Outlook - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

BioAtla stock price target cut to $10 at BTIG, retains Buy rating - Investing.com Canada

Mar 28, 2025
pulisher
Mar 28, 2025

BioAtla stock price target cut to $10 at BTIG, retains Buy rating By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

BioAtla Inc. (BCAB) reports earnings - Quartz

Mar 28, 2025
pulisher
Mar 28, 2025

BioAtla, Inc. SEC 10-K Report - TradingView

Mar 28, 2025
pulisher
Mar 28, 2025

BioAtla Inc: Weathering Stock Market Storms with 22.78M Market Cap - investchronicle.com

Mar 28, 2025
pulisher
Mar 27, 2025

BioAtla, Inc. Reports 2024 Financial Results and Clinical Progress - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Earnings call transcript: BioAtla Q4 2024 sees strategic cost cuts, stock rises By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Earnings call transcript: BioAtla Q4 2024 sees strategic cost cuts, stock rises - Investing.com India

Mar 27, 2025
pulisher
Mar 27, 2025

BioAtla announces restructuring, to cut over 30% of workforce - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

BioAtla reports Q4 Net loss ($14.9M) vs ($26.9M) last year - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Bioatla IncAnnounces 30% Workforce Reduction - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress - The Manila Times

Mar 27, 2025
pulisher
Mar 26, 2025

Earnings Outlook For BioAtla - Benzinga

Mar 26, 2025
pulisher
Mar 20, 2025

BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings - Quantisnow

Mar 20, 2025
pulisher
Mar 20, 2025

BioAtla, Inc. Announces Abstract Presentations at European Lung Cancer Congress and Mayo Clinic Symposium 2025 - Nasdaq

Mar 20, 2025
pulisher
Mar 19, 2025

BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025 - Quantisnow

Mar 19, 2025

Bioatla Inc Stock (BCAB) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Cap:     |  Volume (24h):